Another NICE no for Dendreon cancer drug
January 13, 2015Sales and Marketing Cancer, Dendreon, FDA, NHS, NICE, Provenge, sipuleucel-T
Dendreon has seen its prostate cancer treatment for people whose disease has spread and who are not yet suitable for …
NHS drops 25 treatments from Cancer Drugs Fund
January 12, 2015Sales and Marketing Afinitor, CDF, Cancer, Cancer Drugs Fund, Eisa, Halaven, Heribulin, Jevtana, NHS, Sanofi, Zaltrap, aflibercept, cabazitaxel, everolimus
Twenty-five cancer treatments will be removed from the Cancer Drugs Fund list, NHS England has announced. Having concluded its review …
AstraZeneca drops CDF application
January 12, 2015Sales and Marketing AstraZeneca, CDF, Cancer, NHS, NICE, lynparza, olaparib
AstraZeneca has withdrawn its application for its drug Lynparza to be on the Cancer Drugs Fund (CDF), citing concerns with …
Novartis enters digital tech collaboration
January 12, 2015Sales and Marketing Novartis, clinical trials, digital, mhealth, qualcomm, ventures
Novartis has entered an agreement with the US investment company Qualcomm Ventures to create a joint firm to support the …
Shire buys rare-disease firm NPS Pharma
January 12, 2015Sales and Marketing AbbVie, Shire, gattex, natpara, nps, nps pharma
Shire is to acquire rare diseases firm NPS Pharma to enhance its profile following the collapse of its deal with …
Roche stakes $1 billion in cancer gene research firm
January 12, 2015Research and Development, Sales and Marketing Cancer, Foundation Medicine, Genentech, Roche, genomics, jp morgan
Roche has announced a huge billion-dollar investment in the cancer genomics research firm Foundation Medicine. Timed with the beginning of …
Daiichi-Sankyo pays $39m to settle allegations
January 12, 2015Sales and Marketing Azor, Benicar, Daiichi Sankyo, Daiichi-Sankyo, Tribenzor, Welchol, kickbacks, us justice
Daiichi-Sankyo will pay the US government and state Medicaid programmes $39 million to resolve claims that it violated the False …
FDA approvals: 1996 versus 2014
January 12, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, John LaMattina, LaMattina, NDA, US, appovals, drugs
As highlighted in a number of recent stories, 2014 was a banner year for the biopharmaceutical industry with 41 new …
Heptares Therapeutics hires former GSK heads
January 12, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Atul Pande, GSK, Heptares, Roberto Solari
UK and US-based clinical-stage drug firm Heptares Therapeutics has appointed Atul Pande and Roberto Solari to its board of directors. …
Daiichi-Sankyo blood drug gets FDA nod
January 12, 2015Sales and Marketing BMS, Daiichi Sankyo, Daiichi-Sankyo, FDA, Pfizer, Pradaxa, atrial fibrillation, blood, savaysa
The US Food and Drug Administration has shown Daiichi-Sankyo’s anti-clotting drug Savaysa the green light to reduce the risk of …
Mixed results for Biogen’s MS drug
January 9, 2015Sales and Marketing Anti-LINGO-1, BIIB033, Biogen IDEC, MS, multiple sclerosis, plegridy
An experimental drug from Biogen Idec for the treatment of multiple sclerosis (MS) has shown a mixed bag of results …
Takeda trials Teva Parkinson’s drug in Japan
January 9, 2015Sales and Marketing Azilect, CHMP, Copaxone, Parkinson's, Takeda, rasagiline
Takeda has begun late stage trials for Teva’s Parkinson’s disease drug Azilect in Japan, with the hopes of bringing the …
Sanofi and Regeneron post positive alirocumab results
January 9, 2015Sales and Marketing Regeneron, Sanofi, cholesterol, heart, statin, statins
The latest trials of the potentially blockbuster new heart drug alirocumab show it lowers cholesterol in people at moderate and …
Ashfield Meetings & Events makes two appointments
January 9, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Meetings, ashfield, events, ian anderson, jo brook
Healthcare event management firm Ashfield Meetings & Events has appointed Jo Brook as an engagement director and Ian Anderson joins …
Late-stage failure for Otsuka and GW cancer pain drug
January 9, 2015Sales and Marketing Cancer, Epidiolex, GW, MS, NICE, Otsuka, Sativex, cannabidiol, nabiximols
Otsuka and GW Pharmaceutical’s multiple sclerosis drug Sativex has failed to meet the primary endpoint in its first Phase III …
Genentech makes $10m gene testing outlay
January 8, 2015Medical Communications, Research and Development, Sales and Marketing 23andME, DNA, Genentech, MHRA, Pfizer, Roche
Genentech has thrown its weight behind the contentious DNA testing company 23andMe, by agreeing a deal to buy the genomic …
Sandoz earns historic first FDA biosimilar vote
January 8, 2015Sales and Marketing FDA, Humira, Novartis, Sandoz, Zarxio, filgrastim, zarzio
Sandoz has taken a huge step forward in the race to be the first company to market a biosimilar in …
Isis and J&J sign RNA deal
January 8, 2015Research and Development, Sales and Marketing Isis, J&J, JJ, Janssen, RNA, gastrointestinal tract
Isis Pharmaceuticals is collaborating with Johnson & Johnson’s pharma unit Janssen to develop antisense drugs to treat autoimmune disorders. The …
NHS searches for healthcare innovators
January 8, 2015Medical Communications, Sales and Marketing NHS, UK, innovation, programme, sir bruce keogh
NHS England and medical director Sir Bruce Keogh have launched an NHS Innovation Accelerator Programme. The initiative will invite healthcare …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
